Provider: Alpha Street Research
Provider: Edison Investment Research
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Esperion Therapeutics Inc Announces Exercise Of Underwriters’ Over-Allotment Option For Initial Public Offering
Esperion Therapeutics Inc announced that the underwriters of its recently completed initial public offering (IPO) have exercised in full their option to purchase an additional 750,000 shares of common stock from Esperion to cover over-allotments. The sale of the additional shares closed on July 11, 2013. Including proceeds from the sale of the additional shares, the net proceeds to Esperion from the IPO are expected to be $72.8 million after deducting underwriting discounts and commissions and estimated offering expenses payable by Esperion. Credit Suisse and Citigroup acted as joint book-running managers for the offering. JMP Securities and Stifel acted as co-managers.
Latest Key Developments in Biotechnology
- Perrigo Co And Elan Corporation plc receive Irish High Court approval for Perrigo's proposed acquisition of Elan
- AcelRx Pharmaceuticals Inc presents ARX-04 dose-finding phase two study data at Anesthesia Medical Conference
- AVEO Oncology provides update on interim analysis from Tivozanib trial in colorectal cancer
- Evotec AG lowers its 2013 revenue guidance lower than analysts estimates
- Share this
- Digg this